Psoriasis Clinical Trials

I1F-MC-RHBA – UNCOVER-1 Study of Efficacy and Safety of ixekizumab Compared With Placebo and etanercept in Moderate to Severe Plaque Psoriasis Subjects. – ACTIVE/NOT ENROLLING

  • This is a 5 year, Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long-Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis.

ESPRIT Chronic Plaque Psoriasis Registry – ACTIVE/NOT ENROLLING

  • ESPRIT is a 10 year registry of patients taking HUMIRA® for Psoriasis. Patients who volunteer to participate will be asked to provide information about their medical history and experiences with HUMIRA®. No registry specific testing will be performed. Patients will be asked to provide data on their experiences with HUMIRA® approximately every 6 months, or as determined by the study doctor. No drug will be provided as a result of participation in the registry. All treatment decisions are independent of participation in the registry. This is an ongoing trial, but we are no longer enrolling.

Novartis Protocol CAIN457AUS02: A randomized, double-blind, placebo-controlled, parallelgroup, multicenter study to evaluate the effect of secukinumab on aortic vascular inflammation and cardiometabolic biomarkers after 12 weeks of treatment, compared to placebo, and up to 52 weeks of treatment with secukinumab in adult subjects with moderate to severe chronic plaque-type psoriasis – ACTIVE/NOT ENROLLING

  • A Phase IV clinical trial investigating psoriasis and cardiac vascular inflammation, using a biologic IL-17 inhibitor (cosentyx) in adult subjects with moderate to severe chronic plaque psoriasis

Novartis Protocol CAIN457A2326: A 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator’s Global Assessment after 12 weeks of treatment, compared to ustekinumab, and to assess longterm safety, tolerability, and efficacy in subjects with moderate to severe plaque psoriasis– ACTIVE/NOT ENROLLING

  • A Phase IV clinical trial comparing a biologic IL-17 inhibitor (cosentyx) to a biologic IL-12/23 inhibitor (stelara) in adult subjects with moderate to severe plaque psoriasis.

Corrona Protocol PSO-500: A study of the comparative safety of approved psoriasis therapies in a national cohort of psoriasis subjects treated by dermatologists – ACTIVE/CURRENTLY ENROLLING

  • A Phase IV observational study that compares systemic psoriasis therapies that are available for prescription.

Celgene protocol 826652: A Phase IV, open label study of the effects of apremilast on vascular inflammation and cardiometabolic function in psoriasis  -CURRENTLY ENROLLING

An open label study of apremilast in adult patients with moderate to severe plaque psoriasis.

Lilly protocol I6T-MC-AMAJ: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis -ACTIVE/NOT ENROLLING

  • A phase III trial investigating an il-23 inhibitor in adult patients with moderate to severe plaque psoriasis.

Therapeutics Inc protocol 188-0551-307: A double-blind, randomized, multicenter, vehicle controlled, parallel group comparison study to determine the efficacy and safety of halobetasol propionate spray, 0.05% versus vehicle spray in subjects with plaque psoriasis receiving up to four weeks of twice daily treatment-CURRENTLY ENROLLING

  • A Phase III trial investigating a new formulation of a topical steroid in adult patients with moderate plaque psoriasis.

Abbvie protocol M16-005: A Multicenter, Single-Arm, Open Label, Assessor-Blinded Study to Assess the Usability of the Risankizumab Autoinjector Combination Product in Adult Patients With Moderate to Severe Plaque Psoriasis -CURRENTLY ENROLLING

  • A Phase III trial investigating an autoinjector vs a prefilled syringe of Skyrizi.

The Clinical Research team at DermAssociates is committed to conducting clinical research in accordance with Good Clinical Practices and IHCP guidelines to ensure the trials are carried out safely and ethically. DermAssociates consistently seeks optimal results for its patients and has a proven record of meeting and exceeding expectations.